Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis - Lombardo S, Millar D, Jurkovich GJ, Coimbra R, Nirula R.

BACKGROUND: Recombinant factor VIIa (rFVIIa) has been used off-label as an adjunct in the reversal of warfarin therapy and management of hemorrhage after trauma. Only a handful of these reports are rigorous studies, from which results regarding safety and ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news